In this study, we hypothesized that targeting survivin could be a treatment strategy for HCC and subsequently demonstrated the remarkable heterogeneity of expression of survivin and its phosphorylated active form (p-survivin) in HCC patients' tissues and cell lines. This evidence concerns the gene BIRC5 and hepatocellular carcinoma.